{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-043416","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2026-06-16T11:34:21+00:00","discovered_at":"2026-06-16T11:35:00.395053+00:00","generated_at":"2026-06-16T11:35:15.747119+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acumen nominates two EBD Alzheimer's candidates (ACU301, ACU401); IND in mid-2027","bullets":["Nominated ACU301 (bispecific from sabirnetug) and ACU401 (novel AβO-selective antibody ACU234).","Exercised option under JCR collaboration; combines Acumen's AβO antibody with J-Brain Cargo BBB-penetrating tech.","Preclinical data: 14-40x higher brain penetration in NHPs vs native antibodies; low anemia risk; no adverse events.","IND-enabling activities ongoing; IND submission targeted mid-2027; SC dosing suitability demonstrated."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-043416","json":"https://secwatch.observer/filing/0001628280-26-043416.json","markdown":"https://secwatch.observer/filing/0001628280-26-043416.md","text":"https://secwatch.observer/filing/0001628280-26-043416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026043416/0001628280-26-043416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026043416/abos-20260612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T11:35:15.747119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}